Roche taps neuroscience

Wednesday 25 August 2021
Country

Switzerland

The Roche Group has entered into a collaboration and licensing agreement with Shape Therapeutics Inc of Seattle, US giving it access to an RNA editing technology that reportedly has promise for neurological disorders. Shape was founded in 2018, and since then has raised $147.5 million in Series A and Series B financing rounds. The deal with Roche, announced on 24 August, could generate as much as $3 billion in milestone payments for Shape should the collaboration yield marketable products.